EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #24
Wallach, J; Brandt, SD. 1,2-Diarylethylamine- and ketamine-based new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 305-352. 593 kB. https://doi.org/10.1007/164_2018_148 #DCK
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #E0 LC
Frison, G; Zamengo, L; Zancanaro, F; Tisato, F; Traldi, P. Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance. Rapid Commun. Mass Spectrom., 15 Jan 2016, 30 (1), 151–160. 1.7 MB. https://doi.org/10.1002/rcm.7425 #Deschloroketamine MS,NMR,other
Kruegel, AC; Sames, D; Hashimoto, K. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders. Patent WO 2021/134086 A1, 1 Jul 2021. 19.8 MB. #14 LC,MS,NMR